MedC Biopharma is a clinical-stage company developing a novel treatment for cutaneous T-cell lymphoma, a type of skin cancer that afflicts 100,000 new patients annually.
The company's R&D is based on a combined effort of Professor Hinanit Koltai, the head of medical cannabis research at the national lab in ARO, Israel, and Professor Emmilia Hodek, director of Dermatology, Rabin Medical Center, Israel. The company's R&D pipeline includes two additional skin oncology indications and anxiety-related indications.
Cumulative Funding Raised Over Time ($)
Employees Over Time
MedC Biopharma Climate Tech relevance
null
Latest News
No Data, yet.
Sorry, no content found under this section.
Jan 12, 2021
www.prnewswire.com
MedC Biopharma and Sana Healthcare Partner to Advance Skin Oncology Platform
ARO Volcani Centre in Collaboration with Rabin Medical Centre, and MedC Biopharma Corporation, Announce the publication of its Research in a Peer-Reviewed Scientific Journal - Oncotarget.
#Partners #Investment
Mar 28, 2019
www.newswire.ca
AgMedica Bioscience Inc. Confirms Collaboration on Research Paper Presented During 2019 Institute of Cannabis Research Conference in Colorado
#Partners
Jan 4, 2019
www.civilized.life
Canadian Company Develops Cancer Treatment Using... Civilized
ARO Volcani Centre in Collaboration with Rabin Medical Centre, and MedC Biopharma Corporation, Announce the publication of its Research in a Peer-Reviewed Scientific Journal - Oncotarget.
#Partners #Investment
Mar 28, 2019
www.newswire.ca
AgMedica Bioscience Inc. Confirms Collaboration on Research Paper Presented During 2019 Institute of Cannabis Research Conference in Colorado
#Partners
Jan 4, 2019
www.civilized.life
Canadian Company Develops Cancer Treatment Using... Civilized